Comparison of the effects of polysulfone and polyester-polymer alloy dialyzers on glycemic control in diabetic patients undergoing hemodialysis

Clinical Nephrology

Volumn 71, Issue 5, 2009, Pages 514-520

  Abe, M ^a   Okada, K ^a   Maruyama, T ^a   Ikeda, K ^a   Kikuchi, F ^b   Kaizu, K ^c   Matsumoto, K ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yamato Hospital   (Japan)

^c Social Insurance Yokohama Central Hospital   (Japan)

Author keywords

Diabetes; Glycated albumin; Hemodialysis; High flux dialyzer; Insulin

Indexed keywords

ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; C PEPTIDE; ETHYLENE VINYL ALCOHOL COPOLYMER; GLITAZONE DERIVATIVE; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; MITIGLINIDE; POLY(METHYL METHACRYLATE); POLYESTER; POLYETHERSULFONE; POLYMER; POLYSULFONE; SULFONYLUREA; ALLOY; BIOMATERIAL; POLYSULFONE P 1700; SULFONE;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; EQUIPMENT DESIGN; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; INSULIN CLEARANCE; MALE; METABOLIC PARAMETERS; TREATMENT OUTCOME; ARTIFICIAL MEMBRANE; BLOOD; FOLLOW UP; INSTRUMENTATION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ALLOYS; BIOCOMPATIBLE MATERIALS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYESTERS; POLYMERS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RENAL DIALYSIS; SULFONES; TREATMENT OUTCOME;

EID: 67649391107     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71514     Document Type: Article

References (28)

1. Abe M, Kaizu K, Matsumoto K. Plasma insulin removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther Apher Dial. 2007a; 11: 280-287.
2. Abe M, Kaizu K, Matsumoto K. Evaluation of the hemodialysis-induced changes in plasma glucose and insulin concentrations in diabetic patients: comparison between the hemodialysis and non-hemodialysis days. Ther Apher Dial. 2007b; 11: 288-295.
3. Abe M, Kikuchi F, Kaizu K, Matsumoto K. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis. Clin Nephrol. 2008; 69: 354-360.
4. Abe M, Matsumoto K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? Nat Clin Pract Nephr. 2008; 4: 482-483.
5. Blankestijin PJ, Vos PF, Rabelink TJ, van Rijin HJ, Jansen H, Koomans HA. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol. 1995; 5: 1703-1708.
6. Cao JJ, Hudson M, Jankowski M, Whitehouse F, Weaver WD. Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus. Am J Cardiol. 2005; 96: 183-186.
7. Chu PL, Chiu YL, Lin JW, Chen SI, Wu KD. Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance. Blood Purif. 2008; 26: 213-220.
8. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO Study. J Am Soc Nephrol. 2003; 14: 3251-3263.
9. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004; 65: 2380-2389.
10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med. 2003; 347: 383-393.
11. Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M et al. Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2004; 8: 443-459.
12. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J AmSoc Nephrol. 2007; 18: 896-903.
13. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002; 39: 297-307.
14. K/DOQI. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007; 49: S1-S179.
15. Mak RH, Wong JH. The vitamin D/Parathyroid hormone axis in the pathogenesis of hypertension and insulin resistance in uremia. Miner Electrolyte Metab. 1992; 18: 156-159.
16. Mak RH. Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol. 1996; 270: 839-844.
17. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001; 24: 909-913.
18. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M et al. Influence of erythropoietin treatment on hemoglobin-A1c levels in patients with chronic renal failure on hemodialysis. Intern Med. 1998; 38: 826-830.
19. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol. 1993; 3: 1409-1415.
20. Schmitz O. Glucose metabolism in non-diabetic and insulin-dependent diabetic subjects with end-stage renal failure. Dan Med Bull. 1991; 38: 32-56.
21. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 1894-1900.
22. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-α: central factors in altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int. 2005; 67: 1216-1233.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
24. Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004; 66: 355-366.
25. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidemia and inflammation in hemodialysis patients. Nephrol Dial Transplant. 2004; 19: 2570-2575.
26. Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ et al. Poor pre-dialysis glycaemic control is a predictor of mortality in Type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 1997; 12: 2105-2110.
27. Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Kratzsch J, Bluher M et al. Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis. Metabolism. 2008; 57: 1414-1421.
28. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant. 2004; 19: v67-v72.